KRIBIOLISA™ Volociximab ELISA

SKU: KBI1733 Category:

₹58,000.00

Enzyme Immunoassay for the estimation of Volociximab in serum and plasma.

About the kit:
– Uses anti-idiotypic monoclonal antibodies which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%


Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Volociximab is a chimeric monoclonal antibody for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of 51 integrin.It is thought to reduce metastases. Early results show potential in renal cell cancers

Intended Use:
For Estimation of Volociximab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.









If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 2000 ng/ml
Specificity

80% – 120% to Volociximab
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring
Entez Gene ID

EOS-200-4 Human
Alternate Names / Synonyms

Volociximab
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products